Skip to main content

Marina Bataller Fernández

Institutions of which they are part

Predoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Vall Hebron Institut de Recerca

Marina Bataller Fernández

Institutions of which they are part

Predoctoral researcher
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Vall Hebron Institut de Recerca

Projects

Overcomming chemoresistance in HNSCC

IP: Matilde Lleonart Pajarin
Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, David Virós Porcuna, Josep Castellví Vives, María Garrido Martínez, Pablo Verges Fort, Marina Bataller Fernández
Funding agency: Fundación hna
Funding: 50000
Reference: FUND.HNA/PREMI/LLEONART/2025
Duration: 01/10/2025 - 30/09/2027

Establecimiento de una estrategia combinada en carcinoma escamoso de cabeza y cuello (HNSCC): una herramienta eficaz para superar los tumores quimiorresistentes.

IP: Matilde Lleonart Pajarin
Collaborators: Katerin Ingrid Rojas Laimito, Yoelsis Garcia Mayea, Juan Lorente Guerrero, Juan Fernando Fuentes Cabrera, Sergio Benavente Norza, Josep Castellví Vives, Marina Bataller Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 240000
Reference: PI24/00630
Duration: 01/01/2025 - 31/12/2027

Nanocápsulas que combinan nuevos fármacos con quimioterapia convencional para curar cánceres resistentes

IP: Matilde Lleonart Pajarin
Collaborators: Katerin Ingrid Rojas Laimito, Irene Braña Garcia, Yoelsis Garcia Mayea, David Virós Porcuna, Juan Fernando Fuentes Cabrera, Josep Castellví Vives, Marina Bataller Fernández
Funding agency: Instituto de Salud Carlos III
Funding: 318750
Reference: AC24/00057
Duration: 01/01/2025 - 31/12/2027

New compounds targeting head and neck cancer as Trojan horses against chemoresistant cells

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Marina Bataller Fernández, Gabriela Isabel Fuentes Llopis
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 20000
Reference: 2023 LLAV 00102
Duration: 01/02/2024 - 31/07/2024

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

Researchers from the Vall d’Hebron Research Institute (VHIR) have participated in a study showing that, after just a few seconds of illumination, the activated molecule prevents the formation of tumor spheres.

Experts addressed the main current and future challenges to improve therapeutic options for patients with this type of tumor.

Related professionals

Carme Cañete Ramirez

Carme Cañete Ramirez

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more
Claudia Borrego Carmona

Claudia Borrego Carmona

Administration and Management
Stroke research
Read more
Albert Lecube Torelló

Albert Lecube Torelló

Main researcher
Diabetes and Metabolism
Read more
Sara Valles Angulo

Sara Valles Angulo

Predoctoral researcher
Neurotraumatology and Neurosurgery Research Unit (UNINN)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.